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Abstract
Degeneration of nigrostriatal dopaminergic system is the principal lesion in Parkinson’s dis-
ease. Because glial cell line-derived neurotrophic factor (GDNF) promotes survival of dopa-
mine neurons in vitro and in vivo, intracranial delivery of GDNF has been attempted for
Parkinson’s disease treatment but with variable success. For improving GDNF-based thera-
pies, knowledge on physiological role of endogenous GDNF at the sites of its expression is
important. However, due to limitations of existing genetic model systems, such knowledge
is scarce. Here, we report that prevention of transcription ofGdnf 3’UTR inGdnf endoge-
nous locus yields GDNF hypermorphic mice with increased, but spatially unchanged GDNF
expression, enabling analysis of postnatal GDNF function. We found that increased level of
GDNF in the central nervous system increases the number of adult dopamine neurons in
the substantia nigra pars compacta and the number of dopaminergic terminals in the dorsal
striatum. At the functional level, GDNF levels increased striatal tissue dopamine levels and
augmented striatal dopamine release and re-uptake. In a proteasome inhibitor lactacystin-
induced model of Parkinson’s disease GDNF hypermorphic mice were protected from the
reduction in striatal dopamine and failure of dopaminergic system function. Importantly,
adverse phenotypic effects associated with spatially unregulated GDNF applications were
not observed. Enhanced GDNF levels up-regulated striatal dopamine transporter activity by
at least five fold resulting in enhanced susceptibility to 6-OHDA, a toxin transported into
dopamine neurons by DAT. Further, we report how GDNF levels regulate kidney develop-
ment and identify microRNAs miR-9, miR-96, miR-133, and miR-146a as negative regula-
tors of GDNF expression via interaction with Gdnf 3’UTR in vitro. Our results reveal the role
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Author Summary
Intracranial delivery of GDNF has been attempted for Parkinson’s disease (PD) treatment
but with variable success. For improving GDNF-based therapies, knowledge on physiolog-
ical role of endogenous GDNF at the sites of its expression is important. However, due to
limitations of existing genetic model systems, such knowledge is scarce. Here, we utilize an
innovative genetic approach by targeting the 3’UTR regulation of Gdnf in mice. Such ani-
mals express elevated levels of Gdnf exclusively in natively Gdnf-expressing cells, enabling
dissection of endogenous GDNF functions in vivo. We show that endogenous GDNF regu-
lates dopamine system development and function and protects mice in a rodent PD model
without side effects associated with ectopic GDNF applications. Further, we report how
GDNF levels regulate kidney development and identify microRNAs which control GDNF
expression. Our study highlights the importance of correct spatial expression of GDNF
and opens a novel approach to study gene function in mice.
Introduction
Exogenously applied glial cell line-derived neurotrophic factor (GDNF) promotes the survival,
function, and neurite growth of nigrostriatal dopamine (DA) neurons both in vitro and in vivo
[1,2]. The classic motor deficit in Parkinson’s disease is characterized by a gradual loss of
nigrostriatal DA neurons, leading to a reduction in striatal dopamine levels, resting tremor,
rigidity, and an inability to initiate voluntary movement [3]. Intracranial delivery of GDNF has
been tested in clinical trials for treating Parkinson’s disease (PD); however, both the efficacy
and the side effects of this treatment vary widely [3–6]. Increasing the therapeutic efficacy of
GDNF requires a better understanding of its physiological role; however, our knowledge
regarding the postnatal role of GDNF is currently limited. Knockout mice that lack Gdnf or its
receptors (Gfrα1 and Ret) die at birth due to a lack of kidneys, but with intact nigrostriatal DA
system which undergoes developmental maturation during the first three post-natal weeks
[7,8]. It has been reported that 50% reduction in GDNF levels in adult Gdnf conditional knock-
out mice has profound consequences on midbrain dopamine neuron survival upon aging [9].
However, our recent study with Gdnf conditional knock-out mice utilizing three Cre systems
including the repetition of the experiments performed in [9] did not reveal loss of DA neurons
after GDNF deletion or reduction at any age [10]. Based on current evidence it is possible that
GDNF either has no physiological role in the brain DA system, that GDNF reduction or dele-
tion in the brain is compensated by another mechanism, or that GDNF regulates the DA sys-
tem at the functional level, rather than at the level of supporting the survival of the DA cell
bodies in the midbrain. Moreover, although GDNF is known to be essential for initiating kid-
ney development [7], our understanding of the role of endogenous GDNF in kidney matura-
tion has remained limited.
Here, we report generation and analysis of mice carrying Gdnf hypermorphic (Gdnfhyper)
allele, generated by insertion of a cassette containing bovine growth hormone polyA signal
after the stop-codon in Gdnf endogenous locus preventing transcription into Gdnf wild type
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3’UTR. These mice have increased–but spatially unchanged–expression of the endogenous
Gdnf gene. While Gdnfhyper/hyper mice die by postnatal day 18 (P18) due to kidney defects,
Gdnfwt/hyper mice are healthy and only display mild occasional reduction in kidney size.
Gdnfwt/hyper animals revealed that GDNF has an important role in the postnatal nigrostriatal
system development and adult function and clarified which aspects of the nigrostriatal dopami-
nergic system structure and function are regulated by GDNF. They also enabled analysis of
GDNF function in kidney maturation beyond the first steps in renal development.
Results
Generation ofGdnf hypermorphic allele and in vitro analysis
In the process of generating a conditional knockout (or “floxed”) Gdnf allele [10], we noted
that the 3’UTR of Gdnf is relatively long and evolutionarily conserved (Fig 1A). Since Gdnf
3’UTR inhibits reporter gene expression in a cell line [11] we decided to analyze Gdnf 3’UTR
function in vivo by insertion of an FRT-flanked puΔtk cassette [12] after the stop codon in the
Gdnf locus in embryonic stem (ES) cells. The puΔtk cassette contains the bovine growth hor-
mone polyadenylation (bGHpA) signal, which induces termination of transcription and is
commonly used in gene-trap experiments in mice (Fig 1B). We used a luciferase-based reporter
assay to confirm that the bGHpA signal prevents transcription into the Gdnf 3’UTR in our con-
struct (S1A and S1B Fig) and yields correctly sized fusion mRNA (S1C Fig). Using a reporter
gene assay, we found an 8-fold increase in luciferase expression from the construct containing
Firefly-puΔtk proceeded by Gdnf 3’UTR (relative to Firefly-Gdnf 3’UTR) in a cell line derived
from human embryonic kidney cells (HEK293) and a 2-fold increase in a cell line derived from
human brain cells (U87) (S1D Fig). We also observed similar inhibitory effects on reporter
gene expression, regardless of whether the Gdnf 3’UTR was cloned downstream of a sea pansy
Fig 1. Gdnf 3’UTR and generation of GDNF hypermorphic allele. (A) The 3’UTR of theGdnfmRNA is
evolutionarily conserved. Exons and the 3’UTR are drawn to scale. Percent of identity between the human
(Hs) and mouse (Mm) sequences is indicated. Source: Blast. (B) Schematic representation of theGdnf
hypermorphic allele. A andC designate the primers used forGdnfmRNA sequence analysis in targeted mice
(see S2F and S2G Fig); primers A and B were used forGdnfQPCR. The bGHpA, puΔtk, loxP sites (black
triangles), and F-FRT sites are indicated. The blue and red bars indicate the probes used for in situ
hybridization.
doi:10.1371/journal.pgen.1005710.g001
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(Renilla reniformis) or Photinini firefly (Photinus pyralis) luciferase in both cell lines (S1E Fig),
suggesting that the inhibition of expression by Gdnf 3’UTR is not limited to one cell type or
dependent on the preceding gene. Blocking transcription with actinomycin D revealed that the
Firefly-puΔtk yields a more stable gene product than Firefly-Gdnf 3’UTR, suggesting that nega-
tive regulation via Gdnf 3’UTR occurs at the post-transcriptional level (S1F Fig).
Next, we generated mice carrying the Gdnf-FRT-puΔtk-FRT-Gdnf 3’UTR allele (S1G–S1I
Fig). Based on the above experiments and a previously published study [11] the allele was
hypothesized to result in elevated expression of endogenous Gdnf (Fig 1B, S1D–S1F Fig).
Homozygous GdnfpuΔtk/puΔtkmice died before P18 due to extremely small, morphologically dis-
organized kidneys (see below). In contrast, kidney defects were mild (or absent) in heterozy-
gous mice (S1 Table), which were born at the expected Mendelian frequency (S2 Table) and
appeared otherwise phenotypically normal (see below).
Analysis ofGdnfmRNA expression levels and sites in peripheral tissues
ofGdnf puΔtkmice
We first measured the location and levels of Gdnf expression in the developing kidney, testis and
developing hind limb where the expression sites of Gdnf are well established [13,14], http://
developingmouse.brain-map.org. Because antibodies that selectively and specifically bind endoge-
nous GDNF protein in histology sections are not currently available, we used in situ hybridization
to detect GdnfmRNA. During embryonic kidney development, the expression of Gdnf is limited
to a structure of metanephric mesenchyme called cap condensate, which surrounds a Gdnf-nega-
tive epithelial ureteric bud (Fig 2A). A probe spanning the Gdnf-coding sequence (comprising
exons 1 through 3) revealed a GdnfpuΔtk allelic dose-dependent increase inGdnfmRNA levels, but
no difference in the site of expression between wild-type, heterozygous, and homozygous mice
(Fig 2B, upper panel). Thus we designated the GdnfpuΔtk allele as Gdnf hypermorphic or Gdnfhyper
allele. Further analysis revealed that a probe complementary to 525 bp of the 3’ end of the Gdnf
3’UTR revealed fewer Gdnf 3’UTR-containing transcripts inGdnfwt/hypermice compared to
Gdnfw/wtmice. As expected, no signal was detected inGdnfhyper/hypermice using this probe (Fig
2B, lower panel), suggesting that transcription of Gdnfwt 3’UTR is prevented by the puΔtk cas-
sette, as it did in cell line (S1B Fig). A similar increase inGdnf expression was measured in Sertoli
cells (in the testes) and in the developing hind limbs (S2A and S2B Fig). Quantification of Gdnf
mRNA and GDNF protein levels in the developing kidneys and testes also revealed a Gdnfhyper
allelic dose-dependent increase in both organs (Fig 2C–2E, S2C and S2D Fig), and removal of the
puΔtk cassette by crossing with Deleter-FLPmice (Fig 1B; “Gdnf 3’UTRrest/restmice”) restored
GDNF expression to wild-type levels (Fig 2E, S2C and S2D Fig). Thus, we concluded that the
Gdnfhyper allele indeed resulted in elevated expression of GDNF in peripheral tissues.
To further analyze the Gdnf transcript in Gdnfhyper mice we applied Northern blotting to
analyze GdnfmRNA in testis. We observed a major band at the expected size of the predicted
Gdnf-puΔtk fusion transcript (S2E Fig). We also sequenced the Gdnf transcripts from testis in
Gdnfwt/wt, Gdnfhyper/hyper, and Gdnf 3’UTRrest/restmice using RT-PCR. We used a forward
primer spanning Gdnf exon 2 and a reverse primer spanning puΔtk (starting 428 bp down-
stream from the TGA stop codon of Gdnf) (S2F and S2G Fig); our analysis revealed a Gdnf-
puΔtk fusion transcript with the predicted size and sequence (S2G Fig).
Kidney size and morphology are negatively regulated by excess GDNF
levels
Ureteric bud outgrowth–the first step in kidney development–is induced by GDNF [7]. Thus,
homozygous Gdnf-knockout mice lack kidneys, and 20–30% of heterozygous GDNF-knockout
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PLOS Genetics | DOI:10.1371/journal.pgen.1005710 December 17, 2015 4 / 24
mice have only one kidney [15]. In vitro, exogenous GDNF promotes the growth of ectopic
ureteric buds in embryonic tissue explants and expansion of endogenous ureteric buds tips
[16]. However, how endogenous GDNF regulates subsequent steps in kidney development in
Fig 2. Gdnf levels are a critical determinant of embryonic renal growth andmorphogenesis. (A) Schematic representation ofGdnf expression (blue) in
the mouse kidney at E11.5. (B) Representative image of in situ hybridization ofGdnfmRNA (blue) in the urogenital tract of E11.5 mice. N = 4 mice/group.
(C-E)GdnfmRNA [E14.5 (C) and E18.5 (D)] and protein [E18.5; (E)] levels in the kidney measured using QPCR (C and D) and ELISA (E). N = 2–10 mice/
group. (F) Representative image of kidneys obtained from P7.5 mice. (G) Representative image of hematoxylin-and-eosin-stained sections from E18.5
kidneys. The renal cortex is indicated with a yellow bar, the medulla is indicated with a green bar, and collecting duct cysts are indicated with yellow
arrowheads. (H) At the time of renal differentiation initiation (E11.75), a wild-type kidney (left) contains a typical UB branching pattern with an interim stalk (red
arrowhead), elongated ureter stalk (white arrowhead), and locally enlarged UB tips (arrows). In contrast, a kidney from aGdnfhyper/hyper embryo (right)
contains one large UB that appears bumpy (arrows), lacks an interim stalk, and lacks normal elongation of the UB (white arrowhead). (I) Images of a wild-type
(left) andGdnf hyper/hyper (right) kidney at E13.5; the kidney from theGdnf hyper/hyper embryo is smaller in size, has enlarged ureteric buds (arrows), and
shortened stalks (arrow head). For F-I, N = 3–20 mice/group. Scale bars: B, 10 μm; F, 1 mm; G, 300 μmH, 50 μm; I, 100 μm. Abbreviations: E, embryonic
day; MM, metanephric mesenchyme; P, postnatal day; UB, ureteric bud. In this and subsequent figures, all summary data are presented as the mean ± SEM;
*P<0.05, **P<0.01, and ***P<0.001; Student’s t-test, unless noted otherwise.
doi:10.1371/journal.pgen.1005710.g002
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vivo is poorly understood. In vitro GDNF protein application studies [16] and results from the
Gdnf knockout mice [15] suggest that the overexpression of Gdnf in our hypermorphic mice
might cause enlargement of the kidneys. In contrast, we found that overexpression of GDNF
negatively regulates kidney size and morphological maturation (Fig 2F and 2G; S1 Table) in a
concentration-dependent manner (Fig 2B–2E). An analysis of the early steps in kidney devel-
opment (i.e., in E11.5 through E11.75) in Gdnfhyper/hyper mice revealed that excess GDNF (Fig
2B, upper panel) induces hypertrophic ureteric bud formation and impairs the development
and elongation of the stalk (Fig 2H). At mid-gestation (i.e., E13.5), these enlarged ureteric buds
and absent or shortened stalks are still observed, and the initial signs of reduced kidney size
emerge (Fig 2I). During late embryogenesis, the kidneys in Gdnfhyper/hypermice fail to reach
normal size, resulting in severe renal hypodysplasia with disorganized medulla-cortex
compartmentalization, reduced cortical and medullar areas, and cysts in the collecting ducts
(Fig 2G). An analysis of kidney function by measuring serum electrolytes revealed that the kid-
neys of Gdnfhyper/hyper mice function poorly (S2H and S2I Fig). However, in Gdnfwt/hyper mice
the kidney function remains relatively normal (S2H–S2K Fig). Finally, renal development was
restored by crossing with Deleter-FLP mice (Gdnf 3’UTRrest/rest; S2L Fig). These data indicate
that in kidney development, the correct GDNF levels are important as both lack of GDNF and
excess GDNF result in failure of kidney development and function. Importantly, in Gdnfwt/hyper
mouse the kidneys were functional and mice were healthy, providing us a unique animal
model to study the postnatal function of GDNF in the CNS.
Analysis ofGdnfmRNA expression levels and sites in the CNS of
Gdnf hypermice
Next, we set to analyze the site of Gdnf expression in the CNS of GDNF hypermorphic mice. We
utilized in situ hybridization analysis of GdnfmRNA in thalamic nuclei and spinal cord and
observed identical spatial expression patterns between genotypes (Fig 3A and 3B). In the striatum,
whereGdnfmRNA levels peak at P12.5 [17,18], the spatial pattern of Gdnf expression was limited
to a discrete set of sparsely distributed cells, interspaced withGdnf nonexpressing cells, consistent
with previous reports [17,19] and similar betweenGdnfwt/hyper andGdnfwt/wtmice (Fig 3C). In the
striatum,Gdnf is expressed primarily by parvalbumin (Pvalb)—expressing inhibitory neurons
[17]. We therefore used RNAscope, a novel high-sensitivity in situ hybridization method for dou-
ble-staining Pvalb and GdnfmRNAs in histological sections [20]. First, we verified the specificity
of RNAscope probes for Pvalb and GdnfmRNA in the adult cerebellum and E14.5 kidney (S2M
Fig), where the expression of Pvalb and Gdnf, respectively, has been well characterized. Pvalb/Gdnf
double-staining of the striatum of adult mice confirmed that the expression of Gdnf inGdnfwt/hyper
mice is largely retained to Pvalb-expressing cells, similar to wild-type controls (Fig 3D and 3E).
To assess the level of GdnfmRNA in several CNS regions including dorsal striatum, olfactory
bulb, hypothalamus, ventral striatum, ventral midbrain and cerebellum in P7.5 Gdnfwt/hyper and
Gdnfhyper/hyper animals and in 2.5–3 month old adult Gdnfwt/hypermice we utilized quantitative
RT-PCR. We observed an increase ofGdnfmRNA inGdnfwt/hyper and Gdnfhyper/hypermice in
comparison to wild-type littermate controls (Fig 3F and 3G). To examine whether the increase in
GdnfmRNA level is reflected in the GDNF protein levels we used ELISA assay and noted that
GDNF protein levels were increased by approximately two fold in the dorsal striatum of adult
Gdnfwt/hypermice (Fig 3H). Notably, we observed no elevation inGdnfmRNA levels in the sub-
stantia nigra of adultGdnfwt/hypermice (Fig 3G). We conclude that elevation inGdnfmRNA
expression inGdnfhypermice occurs in most brain structures which naturally express Gdnf in the
brain, and that GdnfmRNA and protein levels in the dorsal striatum of adult Gdnfwt/hypermice
are two fold increased.
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Fig 3. Gdnf expression is increased in cells that normally expressGdnf. (A) In situ hybridization showingGdnfmRNA expression in thalamic nuclei at
P7.5 (white arrowheads). (B) In situ hybridization showingGdnfmRNA expression in Clarke’s column in the thoracic part of the spinal cord at P12.5 (white
arrowheads). (C)GdnfmRNA-positive cells (black dots) in the whole striatum (upper panel); a magnified view ofGdnfmRNA-positive cells (arrowheads) is
shown in the lower panel. (D) Representative images of Pvalb (PV, blue) andGdnf (red) mRNA in the striatum of 3-month-old mice detected using
RNAscope. (E) Summary of PV-positive only,Gdnf-positive only, and double-positive cells in striatal slices obtained fromGdnfwt/wt andGdnfwt/hypermice;
N = 5 animals/group. (F)QPCR analysis ofGdnfmRNA levels in the indicated brain regions in P7.5 mice; N = 6–8 mice/group. (G)QPCR analysis ofGdnf
mRNA levels in the indicated brain regions of adult mice; N = 4–8 mice/group. (H) ELISA analysis of GDNF protein levels in the dorsal striatum of adult mice;
N = 6–8 mice/group. Scale bars: A, 150 μm; B, 200 μm; C (upper panels), 500 μm; C (lower panels), 50 μm; D, 10 μm. Abbreviations: dSTR, dorsal striatum;
OB, olfactory bulb; Hyp, hypothalamus; PFC, prefrontal cortex; vSTR, ventral striatum; Hip, hippocampus; vMB, ventral midbrain; CB, cerebellum; RN, dorsal
raphe nucleus; SC, spinal cord; SN, substantia nigra; VTA, ventral tegmental area; PV, parvalbumin; m, months; P, postnatal day.
doi:10.1371/journal.pgen.1005710.g003
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Increased GDNF levels increase the nigrostriatal dopaminergic system
during development
In the first three postnatal weeks, DA neurons experience several major developmental changes,
including maturation of striatal target innervation and programmed cell death in the substantia
nigra pars compacta [7,8]. The postnatal function of endogenous GDNF in the brain’s dopami-
nergic system is poorly understood [10]. To assess whether increased GDNF levels in the GDNF
hypermorphic mice result in changes in nigrostriatal DA system during development, we first
analyzed the striatal levels of phosphorylated extracellular signal-regulated kinase (Erk) a known
target in GDNF signaling [7] using western blotting. We found that the levels of phosphorylated
ERK2 were increased in the striatum of Gdnfwt/hyper and Gdnfhyper/hypermice at P7.5 (Fig 4A),
indicating increased GDNF signaling. Next, we analyzed rostral brain DA levels and the number
of DA neurons in the substantia nigra pars compacta. We found that at P7.5, DA levels in the
rostral brain were increased by 25% to a similar extent in both Gdnfwt/hyper and Gdnfhyper/hyper
mice, and normalizing Gdnf levels by crossing the mice with Deleter-FLP animals restored DA to
wild-type levels (Fig 4B). Compared to wt mice, the number of DA neurons in the substantia
nigra pars compacta revealed a similar 15% increase inGdnfwt/hyper and Gdnfhyper/hyper animals at
P7.5 (Fig 4C). Finally, the levels of DAmetabolites in the rostral brain were similar between geno-
types at P7.5 (S3A and S3B Fig). The development of the DA system was not linked with kidney
development, as kidney function was severely impaired in the Gdnfhyper/hypermice, but not in the
Gdnfwt/hypermice while the DA system parameters were comparable between the Gdnfwt/hyper and
Gdnfhyper/hypermice. This finding was further supported by the lack of correlation between serum
urea and brain DA levels in individual heterozygous animals at P7.5 (S3 Table). We conclude
that increased GDNF levels increase striatal DA levels and DA cell number in the substantia
nigra pars compacta at P7.5.
Increased GDNF levels increase the nigrostriatal dopaminergic system
in adult mice
To assess whether DA system was changed in adult animals, we studied Gdnfwt/hyper mice at
2.5–4 months of age and noted that the DA levels in the striatum of Gdnfwt/hypermice were
increased by 25% compared to wild-type littermates (Fig 4D). Analysis of striatal DA metabo-
lites (S3C and S3D Fig) revealed a 35–40% increase in 3,4-dihydroxyphenylacetic acid
(DOPAC) levels (S3C Fig), suggesting that also DA release in Gdnfwt/hyper mice may be
increased. To assess the effect of the absence of one Gdnf allele in the comparable genetic back-
ground, we also measured DA levels in heterozygous GDNF-knockout mice (Gdnfwt/KO) [10].
Consistent with previous studies [21] the levels of DA in Gdnfwt/KOmice were similar to wild-
type levels (Fig 4D). Restoring wild-type expression levels of GDNF by crossing Gdnfwt/hyper
mice with Deleter-FLP mice also restored DA levels (S3E Fig). In the substantia nigra pars
compacta the number of DA neurons in the Gdnfwt/hyper mice was 15% increased relative to the
controls (Fig 4E and 4F), indicating that the moderate 15% increase in the number of substan-
tia nigra pars compacta DA neurons noted at P7.5 is retained in adulthood. Similarly, we found
that the number of dopaminergic terminals in the dorsal striatum is increased by 15% in the
Gdnfwt/hyper mice (Fig 4G, S3F Fig). Immunohistochemical examination of nigrostriatal DA
system revealed no gross anatomical differences between the Gdnfwt/hyper and Gdnfwt/wt mice
(S3G and S3H Fig) and the size of the striatum appeared unaffected (S3I Fig).
Collectively, these data indicate that an increase in GDNF expression levels increases the
adult number of DA cells in the substantia nigra pars compacta and the number of dorsal stria-
tal DA terminals by 15%. In addition, increase in GDNF expression increases striatal tissue DA
The Role of Endogenous GDNF in Nigrostriatal Dopamine System Function
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and its metabolite DOPAC levels by 25% and 35–40%, respectively, suggesting that DA release
in Gdnfwt/hyper mice may be enhanced.
Increased GDNF levels increase specific DA system functions in adult
mice
To determine whether increasing the levels of endogenous GDNF affects the function of the
nigrostriatal DA system in adult mice, we performed fast-scan cyclic voltammetry measure-
ments in acute striatal slices at 3–4 months of age, and measured the clearance rate of extracel-
lular exogenous DA in the striatum using in vivo amperometry at the same age. To study
various functional aspects of the DA system, we used a range of stimulation patterns for the
voltammetry measurements (S3J Fig). We observed that stimulations in the striatal tissue of
Gdnfwt/hyper mice released about 35–45% more DA (Fig 4H and 4I) with a steeper rising slope
(S3K Fig) when compared to Gdnfwt/wt mice. No differences were found between the genotypes
in the rise time and decay parameters of the DA events (S3L–S3N Fig). We observed no differ-
ence in paired stimulus depression of DA release (Fig 4J), and we found no difference in DA
release probability (Fig 4K).
Since more DA is released but DA reuptake parameters are comparable between the geno-
types, increased DA uptake in the striatum of Gdnfwt/hypermice can result at least in part, from
the observed 15% increase in the number of dopaminergic terminals in the striatum. However,
increased DA transporter (DAT) levels and/or increased DAT activity could also contribute to
the observed increase in DA re-uptake. To test these possibilities, we measured the clearance
rate of extracellularly applied DA in the striatum using in vivo amperometry. We found that
compared to Gdnfwt/wt mice, DAT activity in the Gdnfwt/hypermice was increased at least up to
five-fold in a DA concentration-dependent manner (Fig 4L). Next, we examined whether this
difference is due to differences in the levels of DAT between genotypes. We measured total and
surface levels of DAT protein in the striata at P7.5 and total DAT levels in the striata of adult
Fig 4. Increased endogenous GDNF expression affects the development and function of the nigrostriatal dopaminergic system. (A) Levels of
phosphorylated ERK2 at P7.5 in the striatum ofGdnfwt/wt,Gdnfwt/hyper andGdnfhyper/hypermice. N = 5 mice/group; ERK was used for normalization. (B) HPLC
analysis of DA levels in the rostral brain; N = 5–8 mice/group (F = 7.44, P = 0.016). (C)Quantification of tyrosine hydroxylase (TH)-positive (a marker of DA
neurons) cells in the SNpc; N = 6–8 mice/group (F = 7.44, P = 0.0048). (D) HPLC analysis of DA levels in the dSTR; N = 11 forGdnfwt/wt, 8 forGdnfwt/hyper
mice/group (P = 0.000164). HPLC analysis of DA levels in the dorsal striatum ofGdnf 3’UTRwt/wt andGdnfwt/KOmice; N = 6 mice/group. (E-F) The number of
TH-positive (E; N = 8Gdnfwt/wt, N = 7Gdnfwt/hyper; P = 0.025) and VMAT2-positive neurons (F; N = 7Gdnfwt/wt, N = 7Gdnfwt/hyper; P = 0.016) in the SNpc. (G)
The number of DAT+ varicosities (N = 9Gdnfwt/wt, N = 7Gdnfwt/hyper; P = 0.042) in the dSTR. (H-K) Cyclic voltammetry analysis of acute striatal slices (see
also S3J Fig); N = 5–7 mice/group with 1–3 slices per mouse. (H) DA release in response to electrical stimulation [two-way repeated measures ANOVA, F
(1,29) = 5.866]; (I) Averaged traces of DA events. (J) Short-term depression of striatal DA release after prior DA exocytosis, shown as percent of the first DA
release. (K) The ratio of DA release after a single stimulus and after a 5 pulse burst at 20Hz. (L) In vivo amperometry following intrastriatal DA injection
reveals that dopamine transporter (DAT) activity inGdnfwt/hypermice is dependent on the concentration of DA; N = 4 mice/group (F = 47.931). (M) Locomotor
activity after an injection of amphetamine (1 mg/kg, i.p.); N = 9–10 mice/group (F = 4.386, P = 0.04). (N) In vivomicrodialysis analysis of extracellular striatal
DA levels; amphetamine was applied as indicated by the horizontal bar; N = 9 mice/group. (O) Cyclic voltammetry analysis shows that amphetamine (5 μM)
depletes stimulated DA release faster in the striata ofGdnfwt/hypermice compared toGdnfwt/wtmice; two-way repeated-measures ANOVA reveals an effect of
time (P<0.0001) and genotype (P = 0.031), as well as an interaction between time and genotype (P = 0.049); N = 6 mice/group with 1–3 slices per mouse.
(P-Q) Analysis of a 6-OHDA induced PDmodel. (P)Quantification of DA in the dSTR 2 weeks after striatal 6-OHDA injection, relative to the intact side
(N = 12Gdnfwt/wt; N = 10Gdnfwt/hyper), (F = 40.62, P = 0.00549, Students t-test). The intact and lesioned side differed significantly (P = 2.71×10−15). (Q)
Quantification of TH-positive neurons in the SNpc 2 weeks after striatal 6-OHDA injection, relative to the intact side, (F = 7.04, P = 0.0143, Students t-test).
The intact and lesioned side differed significantly (P = 3.00×10−11). (R-T) Analysis of a lactacystin-induced PDmodel. (R) The percentage of sugar pellet
retrievals from the contralateral side in the corridor test; N = 5–7 mice/group (F = 6.087, P = 0.033). (S)Quantification of DA, DOPAC, and HVA in the dSTR 5
weeks after supranigral lactacystin injection, relative to the intact side; N = 5Gdnfwt/wt, N = 7Gdnfwt/hyper; P = 0.046 for DA, P = 0.015 for DOPAC, P = 0.011
for HVA. The intact and lesioned side differed significantly; P = 0.00016 for DA, P = 0.015 for DOPAC, P = 0.010 for HVA. (T)Quantification of TH-positive
neurons in the SNpc 5 weeks after lactacystin injection, relative to the intact side; N = 4Gdnfwt/wt, N = 7Gdnfwt/hyper; P = 0.236. The intact and lesioned side
differed significantly (P = 0.00029). (U-W) Evaluation of side effects associated with intracranial ectopic GDNF expression. (U) Spontaneous locomotor
activity in an open field; N = 31–34 mice/group. (V) Food intake by adult mice during a 72-hour period; N = 10 mice/group. (W) Body weight of adult mice;
N = 9–34 mice/group. Abbreviations: DA, dopamine; DOPAC, 3,4-dihydroxyphenylacetic acid; HVA, homovanillic acid; dSTR, dorsal striatum; SNpc,
substantia nigra pars compacta.
doi:10.1371/journal.pgen.1005710.g004
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mice; we found no differences between the genotypes (S4A–S4C Fig). Taken together, our find-
ings suggest that increasing endogenous GDNF levels increases striatal tissue DA content and
striatal DA release and re-uptake without affecting the DA release probability. The observed
increase in striatal DA re-uptake in Gdnfwt/hyper mice is most likely explained by the combined
effects of increased DAT activity and 15% increase in the number of striatal dopaminergic
terminals.
Gdnfwt/hypermice have an increased response to amphetamine
In order to investigate whether increased GDNF levels result in functional consequences in the
DA system in behaving animals we administered amphetamine, a dopaminergic stimulant.
Amphetamine is taken up by the DAT into the presynaptic terminal, where it is then loaded
into synaptic vesicles. Amphetamine releases DA from these vesicles into the cytoplasm and
reverses its active transport across the presynaptic membrane; the result is increased DA con-
centration in the synaptic cleft and increased locomotor activity in treated animals [22]. Com-
pared to Gdnfwt/wt littermates, Gdnfwt/hyper mice had increased amphetamine-induced
locomotor activity (Fig 4M), suggesting that amphetamine has a stronger effect in terms of
driving higher extracellular DA levels in the striatum of Gdnfwt/hyper mice. To test this hypothe-
sis, we measured extracellular dopamine levels in the striatum following local amphetamine
delivery via in vivomicrodialysis. Consistent with our hypothesis, we observed an increase in
amphetamine-induced extracellular DA levels in the striata of Gdnfwt/hyper mice (Fig 4N). We
also measured the effect of amphetamine in striatal slices using cyclic voltammetry. Because
amphetamine depletes DA from nerve terminals, cyclic voltammetry can detect the gradual
decrease in stimulated DA release following amphetamine application. Consistent with
increased DAT function in Gdnfwt/hyper mice, we found that amphetamine depletes the synaptic
DA storages with a faster time course in Gdnfwt/hyper mice compared to Gdnfwt/wt littermate
controls (Fig 4O).
Based on these results, the increased amphetamine-induced locomotor activity inGdnfwt/hyper
mice is likely due to a combination of three effects. First, the increased DAT activity inGdnfwt/
hypermice likely causes amphetamine to accumulate in the nerve terminals more rapidly. Second,
the 15% increase in the number of striatal dopaminergic terminals increases the number of stria-
tal DA release sites. And third, more DA is released by the terminals. Collectively, these DA
system features explain the increased amphetamine-induced locomotor activity inGdnfwt/hyper
mice.
Increasing GDNF levels protects the dopaminergic system in a
lactacystin-induced model of Parkinson’s disease
Currently, no mouse model is available that phenocopies the slow disease progression of
patients with PD [23]. Thus, the most widely used animal models for studying PD are based on
the toxins MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and 6-hydroxydopamine
(6-OHDA), both of which are taken up specifically into DA neurons via the DAT [23]. Given
that we found at least up to five-fold increase in DAT activity in Gdnfwt/hypermice, we expect
Gdnfwt/hyper mice to be sensitized to DAT-based toxins, unless the trophic effect of increased
endogenous GDNF expression dampens or reverses the phenotype. We found that relative to
the controls, Gdnfwt/hyper mice are five-fold more sensitive to striatal 6-OHDA injection. More
specifically, following striatal 6-OHDA injection we found five-fold aggravated decrease in
striatal DA levels and two-fold aggravated decrease in substantia nigra pars compacta DA neu-
ron numbers in Gdnfwt/hyper mice relative to the littermate controls (Fig 4P and 4Q). To over-
come the confounding effect of enhanced DAT activity in Gdnfwt/hyper mice in DAT based PD
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models, we looked for alternative models of PD. Abnormal aggregation of proteins is a gener-
ally accepted pathological process common to most neurodegenerative disorders, including
PD. Consistent with this notion, intracranial application of proteasome inhibitors such as lac-
tacystin can induce a PD-like phenotype in both rodents and fish [24,25]. We found that uni-
lateral lactacystin injection just above the substantia nigra induced significant side bias
(measured using the corridor test) in Gdnfwt/wt mice; however, lactacystin-injected Gdnfwt/hyper
mice did not develop this bias (Fig 4R). In addition, DA and its metabolite levels were better
preserved in the striatum of lactacystin-injected Gdnfwt/hypermice compared to lactacystin-
injected wild-type mice (Fig 4S). However, the number of DA cells in the substantia nigra pars
compacta was comparably reduced by lactacystin injection in both genotypes (Fig 4T), suggest-
ing that the protective effect from lactacystin-induced PD in Gdnfwt/hyper mice occurs at the
functional level in the striatum.
GDNF derepression does not induce side effects associated with
ectopic GDNF application
Despite its dopaminotrophic benefits both in PD models and in clinical trials, the delivery of
GDNF to the nigrostriatal DA system also induces adverse side effects, including hyperactivity
[5,26–29], reduced levels of striatal tyrosine hydroxylase (TH)–the rate-limiting enzyme in DA
synthesis [5,30], reduced food intake, and loss of body weight [6,26]. Importantly, none of
these effects were observed in our Gdnfwt/hyper mice as assessed by open field test, measure-
ments of food intake in physiological cage, bodyweight measurements of adult mice at 3–4
months of age (Fig 4U–4W) and by western blotting and immunohistochemical measurements
of striatal TH levels at P7.5 and in adult mice at 3–4 months of age (S4D–S4G Fig).
miR-9, miR-96, miR-133 and miR-146a are novel regulators of GDNF
To get insight on the mechanism how Gdnf 3’UTR negatively regulates gene expression (S1D–
S1F Fig) we looked for trans-acting factors that regulate transcripts containing the Gdnf
3’UTR. Sequence analysis revealed three putative binding sites for RNA-binding proteins
(RBPs) and conserved binding sites for several miRNAs in the Gdnf 3’UTR (Fig 5A). We found
that the RBPs tristetraprolin (TTP, a negative regulator of brain-derived neurotrophic factor
BDNF [31]); embryonic lethal abnormal vision-like protein 1 (ELAVL1); and the AU-rich ele-
ment-binding protein AUF1 had little or no effect on the expression of a reporter construct
containing the Gdnf 3’UTR (S4H Fig), consistent with a previous report [11].
Next, we investigated the effect of miRNAs on regulating Gdnf expression. We examined
the miRNAs miR-133a, miR-133b, miR-125a-5p, miR-125b-5p, miR-30a, miR-30b, miR-96,
miR-9, and miR-146a, which were selected based on their co-expression with Gdnf in several
brain areas [17,19,32,33]; see also www.microrna.org and presence of conserved binding sites
within Gdnf 3’UTR (Fig 5A; www.targetscan.org). Our analysis of miRNA expression revealed
that miR-9, miR-133a, miR-133b, miR-125a-5p, miR-125b-5p, miR-30a, miR-30b, and miR-
146a are all expressed in the developing forebrain, adult dorsal striatum and in the developing
kidney (S4 Table). Next, we transfected HEK293 cells with the above-mentioned putative
Gdnf-regulating pre-miRNAs. Compared to the control miRNAs, the specific miRNAs nega-
tively regulated the expression of a reporter construct containing the Gdnf 3’UTR by 30–50%
(Fig 5B). Next, we examined whether the in silico (genie.weizmann.ac.il, www.targetscan.org)
predicted conserved miRNA sites mediate the interaction between these miRNAs and the Gdnf
3’UTR. We paid particular interest to miR-9 and miR-96, as previous data obtained from two
genome-wide screens suggested that these miRNAs interact with GdnfmRNA in the mouse
brain; and overexpressing them in human cell line suppresses the expression of GDNF
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(summarized in [34]). Mutating some of the predicted miRNA seed sites (Fig 5C; see S1 Mate-
rials and Methods for details) in the Gdnf 3’UTR either reduced or abolished the ability of
miR-9, miR-96, miR-133a, and miR-146a to inhibit expression (Fig 5D), suggesting a direct
interaction between these miRNAs and some of the predicted sites in the Gdnf 3’UTR. Based
on in silico analysis, puΔtk contains approximately half the number of potential miRNA-bind-
ing sites and about 10% of the conserved miRNA sites present in the Gdnf 3’UTR (S4I and S4J
Fig). Consistent with this prediction, we found that miRNAs had no effect on expression of a
reporter construct containing the puΔtk-Gdnf 3’UTR cassette (S4K Fig). To analyze the effect
of miR-9, miR-96, miR-133b, and miR-146a on endogenous GDNF expression, we transiently
Fig 5. Identification ofGdnf-regulating miRNAs. (A) Putative miR binding sites cluster within the conserved areas of theGdnf 3’UTR. The miRNAs
underlined with red bars were co-immunoprecipitated withGdnfmRNA in a genome-wide screen of a mouse brain tissue [34]. Predicted putative RNA-
binding protein (RBP) sites are indicated with triangles. Source: Blast, TragetScan, AREsite, and http://servers.binf.ku.dk/antar/; Hs, human; Mm, mouse. (B)
Luciferase expression from a Ren-Gdnf 3’UTR construct after co-transfection with the indicated pre-miRNAs in HEK293 cells. scr1 and scr2 are scrambled
pre-miRNA controls; N = 3 experiments/miRNA with 3–5 biological repeats/miRNA/experiment. (C) Predicted binding sites (ddG<-3) for miR-9 (green), miR-
96 (blue), miR-133a/b (orange), and miR-146a (red) based on “predict microRNA targets” analysis (http://genie.weizmann.ac.il/). Boxes indicate the mutated
miRNA-binding sites in each mutant. Note that miR-9/96/133m contains overlapping sites for miR-9, miR-96, and miR-133, all of which were mutated in this
construct. (D) Luciferase assay of miR-9, miR-96, miR-133a, and miR-146a mutants (mutated sequences indicated with boxes in panel C; scr1 is a
scrambled pre-miRNA control; N = 2 experiments/miRNA with 3 biological repeats/miRNA/experiment. (E-F) Expression of endogenousGDNFmRNA (E)
and GDNF protein (F) is inhibited in U87 cells by co-transfection with the indicated pre-miRNAs; N = 3–4 experiments with 2–3 biological replicates/
experiment. (G) Adenoviral transduction of Cre—but not GFP—in homozygous “floxed” Dicer-1F/F primary cortical neurons increases endogenous GDNF
protein levels; N = 2 experiments with 3–4 mice/group. (H) AAV-based constructs encoding shRNAs against miR-9, miR-96, and miR-146a, as well as siRNA
against Dicer, increase endogenousGDNF expression in HEK293 cells; N = 5 experiments/construct (except for the shRNA against miR-9, where N = 2
experiments/construct) with 2 biological repeats per experiment. Ad, adenovirus; m, mutant.
doi:10.1371/journal.pgen.1005710.g005
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overexpressed these miRNAs in U87 cells (a human glioblastoma cell line that expresses
endogenous GDNF at detectable levels). We found that compared to the control miRNAs,
transient co-expression of these four miRNAs reduced the GdnfmRNA level (Fig 5E) and
GDNF protein level (Fig 5F) without affecting cell survival (S4L Fig).
Dicer is required for the maturation of miRNAs. To gain further evidence that the GDNF
expression is regulated by miRNAs, we next examined the effect of deleting Dicer on endoge-
nous GDNF expression in primary Dicerflox/flox cortical neurons [35] using adenovirus-medi-
ated delivery of Cre. Deleting Dicer resulted in up-regulation of endogenous GDNF expression
in cortical neurons (Fig 5G). Finally, to gain insight into how endogenous miR-9, miR-96 and
miR-146a impact endogenous GDNFmRNA levels in human cells we tested six different
shRNA constructs targeted to each miRNA for their ability to derepress endogenous GDNF
expression in HEK293 cells (S4M Fig). Based on this analysis, we identified the three shRNA
constructs targeting miR-9, miR-96 and miR-146a with the highest potency for derepressing
endogenous GDNFmRNA expression (Fig 5H). An siRNA against Dicer was used as a positive
control (Fig 5H). We conclude that miR-9, miR-96, miR-133, and miR-146a interact directly
with their binding sites in the Gdnf 3’UTR; moreover, miR-9, miR-96, and miR-146a regulate
the expression of GDNF in vitro.
Discussion
Due to the limitations associated with existing genetic tools, the function of endogenous
GDNF has remained poorly understood [7,10]. Despite multiple attempts by several research
groups, transgenic animals in which GDNF expression is restricted to cells that normally
express GDNF are not available. The dramatic consequences of ectopic GDNF expression—for
example, on the development of the urogenital tract [36]—make it difficult to draw conclusions
regarding the function of endogenous GDNF based solely on ectopic GDNF expression in the
brain.
Analysis of GDNF hypermorphic mice
GDNF hypermorphic mice provided us with an opportunity to study the function of endoge-
nous GDNF with the focus on the postnatal nigrostriatal DA system and in renal development.
We found that increasing the endogenous levels of GDNF increases the number of DA neu-
rons in the substantia nigra pars compacta during the development, and that this increase in
DA neuron numbers is retained in adulthood. Highlighting the importance of the correct
expression site, GDNF has no such effects when overexpressed in the mouse brain under the
promoter not specific to GDNF-expressing neurons [8].
In the dorsal striatum, increase in GDNF levels resulted in increased number of dopaminer-
gic terminals, increased levels of DA and enhanced DA release and reuptake, explaining the
enhanced amphetamine-induced locomotor activity in GDNF hypermorphic mice. Since the
nigrostriatal DA system is well known for its capacity to compensate for changes [37], the
observed increase in DA transporter activity in GDNF hypermorphic mice likely reflects a
measure to counterbalance elevated striatal DA content and release to maintain normal extra-
cellular DA levels. We observed no change in striatal DA transporter levels, suggesting that
DAT activity in GDNF hypermorphic mice is regulated by other mechanisms, such as post-
translational modifications or protein-protein interactions. Since currently methods allowing
temporal analysis of those endpoints in the mouse striatum are not available, the question of
how GDNF regulates DAT activity remains to be resolved.
Notably, we found that increased GDNF levels have a protective effect in supranigrally
delivered lactacystin model of Parkinson’s disease; this effect is not mediated by protecting DA
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cell bodies in the substantia nigra pars compacta, but by enhancing the dopaminergic function
in the striatum. These findings are consistent with a previous study reporting the lack of effect
of selective GDNF deletion or reduction on the survival of DA cell bodies in the substantia
nigra pars compacta upon aging [10] and with a study reporting that deletion of GDNF recep-
tor RET does not modulate MPTP toxicity on the dopaminergic system but is required for
regeneration of striatal dopaminergic axon terminals [38]. Collectively, these results suggest
that in adult mice GDNF acts as a local trophic factor for DA axons in the striatum.
Furthermore, our Gdnfwt/hyper mice do not develop any of the adverse side effects usually
associated with ectopic GDNF expression, which can include hyperactivity, loss of body weight,
and a decrease in the levels of tyrosine hydroxylase—the rate-limiting enzyme in DA synthesis.
Because GDNF is not applied ectopically in our model, the common feature in both experi-
mental animals and human studies—specifically, the massive sprouting of DA fibers towards
the site of GDNF delivery, with unknown consequences with respect to side effects, treatment
efficacy and behavior—was not observed in Gdnfwt/hyper mice. Together, these results imply
that measures that promote elevation in endogenous GDNF levels in the striatum may have
clinical potential in the treatment of Parkinson’s disease. However, because we found increased
DAT activity in GDNF hypermorphic mice, the simultaneous use of GDNF with DAT-based
toxins or drugs should be carefully considered and calls for further investigation.
To date, data on GDNF function is mainly gathered using various ectopic GDNF applica-
tion methods in rodent and primate models and using constitutive or conditional GDNF
knock-out mice. Our results bring an important new dimension since we analyze the effect of
the elevation of endogenous GDNF. In Table 1 we illustrate the qualitative difference between
ectopic and endogenous GDNF sources.
With respect to the role of GDNF in renal development, we found that excess GDNF levels
negatively regulate kidney growth and morphogenesis. This result is contrary to expectations
based on the majority of in vitro studies, where the effect of ectopic GDNF on embryonic uro-
genital block can be followed for the few days, and likely arose from an overstimulation of ure-
teric bud growth, a key process in renal development.
A comparison between our Gdnfwt/hyper mice and MEN2B mice, which express a constitu-
tively active form of the GDNF receptor RET [41], revealed several common features and key
differences between these two models. For example, striatal DA levels, TH-positive cell num-
bers, and striatal DAT activity are increased in both mutants. In contrast, only MEN2B mice
develop increased levels of DAT and TH, and reduced spontaneous locomotion [42–44]. Thus,
increasing endogenous GDNF levels is fundamentally different than constitutively activating
RET; this finding may have broad-reaching implications with respect to drug design and stud-
ies of receptor-ligand biology.
miRNAs and regulation of GDNF expression via the 3’UTR
Previously published genome-wide screens suggested that overexpressing miR-9 and miR-96
reduce the levels of GDNFmRNA in a human cell line and that these miRNAs interact with
the GdnfmRNA in the mouse brain [34]. We identified binding sites for miR-9 and miR-96 in
the 3’UTR of Gdnf; in addition, we identified binding sites for miR-133 and miR-146a. We also
found that reducing the levels of Dicer, an enzyme required for the maturation of miRNAs,
derepresses endogenous GDNF expression both in human cells and in mouse primary neurons.
Moreover, overexpressing miR-9, miR-96, miR-133b, and miR-146a represses the expression
of endogenous GDNF mRNA and protein in a human cell line. Finally, we found that shRNAs
against miR-9, miR-96, and miR-146a derepress endogenous GDNFmRNA levels in human
cell line. Taken together, these results confirm the miRNA target in vitro [45]. However, every
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miRNA can have several hundred mRNA targets; thus, assigning specific observations to the
direct effect of a given miRNA acting on one target in vivo is currently not possible. Future
work with a conditional targeting of Gdnf 3’UTR is necessary to overcome this limitation.
Once the effects of adult-onset GDNF elevation in the striatum are characterized, we can then
utilize various anti-miRNA strategies to evaluate a given miRNA’s role in GDNF-induced
Table 1. Summary of GDNF functions identified using GDNF hypermorphic mice. The main findings of this study are reported in comparison with pub-
lished reports from ectopic GDNF applications and GDNF knock-out mice. The forth column indicates whether the observations made in GDNF hypermorphic
mice are consistent with function predicted from ectopic GDNF applications and fromGdnf gene deletion studies, expand the previous knowledge or provide
novel information.
Endogenous GDNF elevation
(this study)
Reported ectopic GDNF expression or gene knock-out approaches Novelty of the
ﬁnding
Observed phenotype Observed phenotype Approach
Increased motor activity upon
amphetamine injection
Increased motor activity upon amphetamine
injection
Nigrostriatal recombinant GDNF
injection and viral gene delivery
[5,26]
Consistent with
ectopic/KO
approaches
GDNF controls DA cell number at P7.5 GDNF controls DA cell number at P7.5 2–3 fold transgenic over-
expression of GDNF in the
forebrain using CaMKIIα
promoter [8]
Consistent with
ectopic/KO
approaches
Striatal DA levels are maintained upon
supra-nigral lactacystin injection
Striatal DA levels are maintained upon supra-
nigral lactacystin injection
Striatal viral gene delivery [39] Consistent with
ectopic/KO
approaches
Increased stimulated and amphetamine
-induced DA release
Increased stimulated and amphetamine
-induced DA release
Intranigral GDNF protein
injection [27,28]
Consistent with
ectopic/KO
approaches
GDNF levels regulate kidney size and
morphological maturation
GDNF is required for the induction of the
ureteric bud development during early
embryogenesis
GDNF gene deletion [15] Consistent and
expanding ectopic/
KO approaches
Elevated GDNF increases the number of
DA neurons and enhances DA system
functionduring development and in
adulthood
GDNF deletion or reduction has no effect on
the number of DA neurons in adulthood and
upon aging; no gross effect on animal behavior
Conditional GDNF deletion or
reduction using three Cre lines
[10]
Novel
Elevated GDNF increases the number of
DA neurons during development which is
retained in adulthood.
Elevated GDNF does not increase the number
of DA neurons after two weeks of age
2–3 fold transgenic over-
expression of GDNF in the
forebrain using CaMKIIα
promoter [8]
Novel
Elevated GDNF increases striatal DA
release and re-uptake
Elevated GDNF has no effect on DA release
and re-uptake
2–3 fold transgenic over-
expression of GDNF in the
forebrain using CaMKIIα
promoter [8]
Novel
No effect on food intake and bodyweight at
least until 3–4 months of age
Reduction in food intake and weight loss within
1–2 weeks after GDNF overexpression
Nigrostriatal recombinant GDNF
injection and viral gene delivery
[6,26]
Novel
No effect on striatal tyrosine hydroxylase
levels at least until 3 months of age
Downregulation of striatal tyrosine hydroxylase
levels after 6 weeks
Nigrostriatal viral gene delivery
[5,30]
Novel
No effect on spontaneous motor activity Spontaneous motor hyperactivity Nigrostriatal recombinant GDNF
injection [26–29]
Novel
Elevation in total striatal DA levels ; No effect on total striatal DA levels; elevation
in DA turnover
Nigrostriatal recombinant GDNF
injection and viral gene delivery
[5,26,28]
Novel
No aberrant sprouting of DA ﬁbers Sprouting of DA ﬁbers towards GDNF injection
site
Nigrostriatal recombinant GDNF
injection and viral gene delivery
[4,26,40]
Novel
Elevated GDNF augments DA
concentration -dependent increase in DAT
activity
Not addressed previously Novel
doi:10.1371/journal.pgen.1005710.t001
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changes in the DA system. Our data also suggest that miR-125a-5p, miR-125b-5p, miR-30a,
and miR-30b are possible regulators of GDNF expression. Whether the effect of these miRNAs
on GDNF expression is direct or indirect warrants further research.
Interestingly, we found that GDNF derepression in GDNF hypermorphic mice was stronger
in the kidneys than in the brain and in the brain areas in which GdnfmRNA levels are higher.
The reasons underlying this finding are currently unknown; however, it may be related to the
relative ratio between the mRNA and miRNAs; in addition, miRNAs can have different effects
on their target mRNAs depending on the tissue context [46].
Conclusions
Using GDNF hypermorphic mice we found that endogenous GDNF regulates postnatal devel-
opment and function of nigrostriatal dopamine system. Moreover, some of the identified
GDNF functions overlapped with results from earlier studies with ectopic GDNF, whereas oth-
ers were novel, highlighting the importance of correct spatial expression of GDNF. We also
found that about two-fold elevation in endogenous GDNF levels protects mice in lactacystin-
based model of Parkinson’s disease without side effects associated with ectopic GDNF applica-
tions. Whether increasing endogenous GDNF levels is a viable strategy for developing new
therapeutic approaches for treating Parkinson’s disease and other diseases is an important
question. Finally, since negative regulation via 3’UTR is shared by many genes, our data pin-
points that 3’UTR-s could provide an important target for genetic studies in vivo. More specifi-
cally, prevention of transcription of negatively regulated 3’UTR-s could provide a measure to
elevate endogenous gene expression while avoiding mis-expression commonly associated with
transgenesis.
Materials and Methods
Detailed descriptions of all materials and methods are provided in S1 Materials and Methods.
Ethics statement
The animal experiments were performed according to the EU legislation harmonized with
Finnish legislation and have been approved by the National Animal Experiment Board of Fin-
land (permit no. ESAVI/3770/04.10.03/2012).
Cell culture and molecular biology assays
Cell culture and molecular biology assays were performed using routine methods in the field;
please see S1 Materials and Methods for details.
Generation of GDNF hypermorphic animals, tissue dissection and
analysis
Briefly, 5667bp 5’ homologous arm spanning the second intron of the Gdnf gene, 6055bp 3’
homologous arm and GDNF protein coding part of Gdnf exon 3 including the stop codon were
amplified with PCR from Gdnf-containing PAC (RP21-583-K20, CHORI) and cloned into
pFlexible [12,47], to generate Gdnf targeted allele. ES clones were screened with standard
Southern blotting. Mice were maintained in 129Ola/ICR/C57bl6 mixed genetic background.
Lactacystin model of Parkinson’s disease
4 μg of lactacystin (AG Scientific) in 4 μl of PBS was injected just above the SN at: antero-poste-
rior (AP) -3.3 mm; medio-lateral (ML) -1.2 mm and dorso-ventral (DV) -4.6 mm. The animals
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were subjected to corridor test 5 weeks after the injection, and sacrificed for tissue isolation and
IHC analysis.
In situ hybridization
In situ hybridization was performed using a probe spanning Gdnf exons or 525bp in the 3’ end
of Gdnf 3’UTR. RNAscope [20] probes detecting Gdnf (red) and Parvalbumin (PV, blue)
mRNA were custom made by Advanced Cell Diagnostics.
Fast-scan cyclic voltammetry
Dopamine release was evoked on acute striatal slices with electrical stimulations and measured
with a carbon fiber electrode calibrated with known dopamine concentrations. The signal was
amplified with Axopatch 200B amplifier (Molecular Devices), digitized (ITC-18 board; Instru-
Tech) and analyzed with a computer routine in IGOR Pro (WaveMetrics).
In vivo chronoamperometry
In anesthetized mice (urethane 1.7–1.9 g/kg, i.p.; Sigma) the electrode was mounted in parallel
with a micropipette used for application of dopamine. Recordings were performed at two ros-
trocaudal striatal tracks in each hemisphere, at AP +0.3 or +1.0 mm; ML ±1.8 mm, using Fast
Analytical Sensing Technology (FAST-16) system (Quanteon). At each recording site, data was
collected from three depths below the dura: at -2.0, -2.5, and -3.0 mm.
In vivomicrodialysis
Amicrodialysis guide cannula (MAB 4.1, AgnTho’s AB) was inserted into the dorsal striatum
(AP +0.6 mm; ML +1.8 mm and DV -2.2 mm) of mice under isoflurane anaesthesia. After
obtaining a stable baseline, the Ringer solution was switched into 100 μM of D-amphetamine
for 60 minutes. The dialysis flow rate was 2 μl/min. Concentration of dopamine was analyzed
using HPLC.
Measurements of GDNF protein levels from tissues
Striatal tissues lysates were prepared and analyzed immediately after sacrificing with GDNF
Emax ImmunoAssay System (Promega).
Behavioral analyses
Open field test was performed in three independent cohorts of comparable size (N = 10–12
male mice per genotype with littermate controls). Metabolic monitoring was performed using
Comprehensive Lab Animal Monitoring System (CLAMS).
Statistical analysis
Statistical analysis for pairwise comparisons was performed using Student’s t-test with two
tailed distribution using the unequal variance option. Data from amperometry was analyzed by
one-way ANOVA followed by Bonferroni post hoc test. Behavioral data were analyzed using
factorial ANOVA design with genotype and cohort as between-subject factors, where appropri-
ate. Post hoc analysis after significant ANOVA was carried out using Student-Newman-Keuls
test. Data from CV was analyzed by two-way repeated measures ANOVA, which in the
amphetamine analysis was followed by multiple comparisons (Sidak´s). All numerical results
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are reported as mean ± standard error of the mean. SPSS (IBM Corp., Armonk NY, USA) or
STATISTICA 11 (StatSoft Inc., Tulsa) were used for analysis.
Supporting Information
S1 Materials and Methods. Detailed description of materials and methods used in this
study.
(DOCX)
S1 Table. GDNF levels regulate kidney size and number. Gdnf KO animals were obtained by
crossing Gdnfwt/hyper animals to Deleter-Cre mice, which results in deletion of GDNF protein
coding exon 3 (Fig 1B) [10].
(DOCX)
S2 Table. Gdnfhyper/hyper mice die before weaning, whereas Gdnfwt/hyper mice are produced
in Mendelian ratios.
(DOCX)
S3 Table. Lack of correlation between serum urea and rostral brain dopamine levels in indi-
vidual Gdnfwt/hyper mice. Correlational analyses of rostral brain dopamine and serum urea lev-
els in individual animals in 10 Gdnfwt/wt and 12 Gdnfwt/hyper animals at P7.5 using the
Correlation function in Microsoft Excel.
(DOCX)
S4 Table. miR expression levels in different tissues and cell lines. Levels of mature miRs
expressed as fold difference relative to sno202 in adult mouse brain, developing mouse kidney
and in HEK293 cells. N = 2 experiments. dSTR, dorsal striatum, E, embryonic day; Hs, Homo
sapiens; Mm,Mus musculus; P, postnatal day; w, weeks.
(DOCX)
S1 Fig. In vitro analysis of Gdnf 3’UTR. (A) Schematic representation of the reporter con-
structs and the derived mRNAs used in this study. Red and blue bar indicate probes used in the
Northern blot for firefly luciferase CDS and Gdnf 3’UTR, respectively. (B) The puΔtk cassette
blocks transcription to the Gdnf 3’UTR, measured by Northern blot analysis of expression
from a construct harboring the Firefly (FF) coding sequence upstream of the puΔtk-Gdnf
3’UTR cassette in HEK293 cells; loading control: 28S ribosomal RNA. (C) Northern blot analy-
sis of expression from construct harboring FF coding sequence proceeded with puΔtk-Gdnf
3’UTR cassette (S1 Fig A) in HEK293 cells (S1 Fig D); loading control: 28S ribosomal RNA.
(D) Expression from equimolar amounts of the FF-Gdnf 3’UTR, FF-puΔtk-Gdnf 3’UTR and
FF-SV40 pA constructs in U87 and HEK293 cells; FF-firefly luciferase; N = 3 experiments/con-
struct with 3 replicates/experiment. (E) Gdnf 3’UTR reduces expression of both Renilla lucifer-
ase (Ren) and FF in HEK293 and U87 cells; N = 3 experiments/construct with 3 replicates/
experiment (F) FF expression from constructs containing SV40 pA, puΔtk-Gdnf 3’UTR cas-
sette and Gdnf 3’UTR in HEK293 cells after treatment with actinomycin D. Note that preven-
tion of transcription of the native Gdnf 3’UTR by preceding puΔtk alleviates the post-
transcriptional inhibition of the reporter. Renilla luciferase expression from a separate plasmid
was used for normalization. N = 3 experiments/construct with 3 replicates/experiment. (G)
Targeting strategy of the Gdnf locus. 5667 bp 5’ (green bar) and 6055 bp 3’ (blue bar) homolo-
gous arms, and Gdnf exon 3 until and including the stop codon were amplified with PCR from
Gdnf-containing PAC and cloned into PmeI, NotI and HindIII sites in pFlexible [31], respec-
tively, to generate Gdnf targeted allele. Sequence lengths are not drawn to scale. Arrows indi-
cate primers used for routine genotyping; black bar indicates probe used for Southern blotting
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using BlpI restriction enzyme shown on (H). (I) Representative image of routine genotyping of
the mice using primers indicated on G. Abbreviations: puΔtk, a cassette with PGK promoter
encoding for fusion protein between puromycin N-acetyltransferase and a truncated version of
herpes simplex virus type 1 thymidine kinase (TK) with 3’ bovine growth hormone polyadeny-
lation signal (pA); FF-firefly luciferase; CDS-coding sequence.
(TIF)
S2 Fig. Analysis of Gdnf expression and kidney function in Gdnf hypermorphic mice. (A-B)
Representative images of in situ hybridization of GdnfmRNA using a probe against the CDS
(stained blue, indicated with white arrow heads) in mice in whole-mount preparations of E11.5
hindlimb (A) and in paraffin sections from P7.5 testis (B). Note that Gdnf expression sites are
comparable between genotypes, whereas the signal appears stronger in Gdnfhyper/hyper mice.
N = 4 mice/group in A and N = 2 in B. (C-D) GdnfmRNA (C) and protein (D) expression in
the testis at E18.5 measured with QPCR and ELISA, respectively, shows allele dose-dependent
increase in GDNF levels in GDNF hypermorphic mice. Note that GDNF protein levels in Gdnf
3’UTRrest/rest mice are normal (D). N = 2–5 mice/group in 2–3 experiments with 2–3 replicates/
experiment (E) Representative image of Northern blot analysis of GdnfmRNA in E18.5 testis
using Gdnf CDS probe. Note that the size of the band is ca 500 bp shorter in Gdnfhyper/hyper
mice compared to the Gdnfwt/wtmice, consistent with the size of transcripts derived from
Gdnf-puΔtk fusion transcript (S1A–S1C Fig; and see S2 Fig F, G). N = 2 mice/group. (F) Sche-
matic representation of the puΔtk-Gdnf 3’UTR (Gdnfhyper) allele for Gdnf, A and B designate
primers used in QPCR analysis of GdnfmRNA levels (C); primers A and C depict primers used
for Gdnf transcript sequence analysis in (G). (G) Representative image of RT-PCR analysis
from E18.5 testis using primers A and C as depicted in (F). The observed PCR product in
Gdnfhyper/hypermice was of expected length (977 bp) and it was sequenced for validation; N = 3
mice; beta-actin was used to verify cDNA quality. (H-I) Kidneys of P7.5 Gdnfhyper/hyper mice
function poorly, as indicated by serum creatinine (H) and serum urea (I) levels. H, N = 3–12; I,
N = 7–26 mice/group. (J-K) The blood serum of adult Gdnfwt/hypermice contains slightly higher
levels of urea (J), but not creatinine (K) compared to wild type mice. Note that two-fold varia-
tion in serum urea levels is considered normal in humans. N = 16–19 mice/group. (L) Repre-
sentative image of kidneys in wild type and Gdnf 3’UTRrest/rest mice. In total, 20 mice were
analyzed from each genotype. (M) Verification of the specificity of RNAscope probes against
parvalbumin (left panel; blue) and Gdnf (right panel; red). Note that the signal matches known
parvalbuminmRNA expression in Purkinje cells (black triangles) and in molecular layer inter-
neurons (open triangles) at three months of age. Similarly, GdnfmRNA can be detected in the
metanephric mesenchyme (MM) and not in the ureteric bud (UB) in the developing kidney at
E14.5. Scale bars: A, 1.5 mm; B, 5 μm; M, 1 mm; L, 70 μm (left) and 100 μm (right). Abbrevia-
tions: bGHpA, bovine growth hormone polyadenylation signal; bp, base pairs; CDS, coding
sequence; Cp, quantification cycle; dSTR, dorsal striatum; E, embryonic day; F, FRT sites for
Flp recombinase; IHC, immunohistochemistry; kb, kilo-base pairs; m, months; MM, meta-
nephric mesenchyme; P, postnatal day; PV, parvalbumin; puΔtk, a cassette with PGK promoter
encoding for fusion protein between puromycin N-acetyltransferase and a truncated version of
herpes simplex virus type 1 thymidine kinase (TK) with 3’ bovine growth hormone polyadeny-
lation signal; UB, ureteric bud. P< 0.05, P< 0.01, and P< 0.001; error bars indicate SEM.
(TIF)
S3 Fig. Analysis of dopamine system development and function in GDNF hypermorphic
mice. (A-B) HPLC analysis of DA metabolites DOPAC (A) and HVA (B) in P7.5 rostral brain.
N = 5–8 mice/group. (C-D)HPLC analysis of DA metabolites DOPAC (C) and HVA (D) in
the dSTR at 2.5–3 months of age. N = 11 for Gdnfwt/wt, 8 for Gdnfwt/hyper; P = 0.00521 for
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DOPAC and P = 0.0569 for HVA. (E)HPLC analysis of DA levels in the dSTR of Gdnf
3’UTRrest/rest and Gdnfwt/wt mice; N = 6 mice/group. (F) Representative images of DAT immu-
nostaining in the dSTR, N = 7–9 mice/group. (G-H) Representative images of TH immunos-
taining in the dSTR (G) and midbrain (H). In total, 8 mice were analyzed from each genotype.
(I) Average striatal area size measured from DAT+ sections. (N = 9 for Gdnfwt/wt, 7 for
Gdnfwt/hyper (J) Representative recording trace of DA events stimulated by single electrical
pulses at 2 min intervals, by paired stimulations at shown intervals, and by a burst of 5 stimuli
at 20 Hz. (K-O) Rise and decay parameters of the first five DA events evoked by single-pulses.
N = 5–7 mice/group with 1–3 striatal slices/mouse analyzed. (K) DA rise slope is steeper
in the striata of Gdnfwt/hyper mice [two-way repeated measures ANOVA, F (1,29) = 11.47,
P = 0.0021], indicating that more dopamine is released from the terminals during the rise
phase. (L) T ½ times, i.e., the width of the event at half of the maximum. (M) Rise time, i.e. the
time for DA events to rise from baseline to the maximum. (N) The fall time of the DA events.
(O) The exponential decay time constant of the DA transients. Abbreviations: DA, dopamine;
DOPAC, 3,4-dihydroxyphenylacetic acid; dSTR, dorsal striatum; HPLC, high performance liq-
uid chromatography; HVA, homovanillic acid; IHC, immunohistochemistry; m, months; P,
postnatal day. Scale bars: F, 10 μm; G, 75 μm; in inset 1 mm; H, 0.5 mm; in inset 30 μm.
(TIF)
S4 Fig. Analysis of DAT and TH protein levels in GDNF hypermorphic mice and identifica-
tion of Gdnf regulating miR-s. (A-B). Total DAT protein levels (A) and plasma membrane
associated DAT levels (B) at P7.5, measured by western blotting. N = 4 mice/group. (C)DAT
protein levels in the dSTR and SNpc at 2.5-3m, measured by western blotting. Gapdh or α-tubu-
lin was used to normalize loading, as indicated in the figure. N = 5 mice/group. (D)OD of striatal
TH+ fibers at P7.5, reflecting striatal TH levels and the density of striatal dopaminergic innerva-
tion at the macroscopic level. N = 7 mice/group. (E) TH protein levels in the dSTR at P7.5, mea-
sured by western blotting. Gapdh was used to normalize loading. N = 4 mice/group. (F)OD of
striatal TH+ fibers at 2.5–3 months of age. N = 10–11 mice/group. (G) TH protein levels in the
dSTR at 2.5–3 months of age, measured by western blotting. Gapdh was used to normalize load-
ing. N = 5 mice/group. (H) Luciferase expression from Firefly-Gdnf 3’UTR construct in HEK293
cells after co-transfection with constructs encoding RBPs. Renilla luciferase expression from a
separate plasmid was used for normalization and GFP was used as a negative control. N = 3
experiments with 3 biological repeats each. (I) The number of predicted miR binding sites
(ddG<0) inGdnf 3’UTR, puΔtk and SV40 late pA signal, analyzed with PITA software [4]. (J)
The number of predicted strong binding sites forGdnf-specific miRs (ddG<-10) inGdnf 3’UTR,
puΔtk and SV40 late pA signal, analyzed with PITA software [4]. Selection of Gdnf-specific miRs
was based on TargetScan analysis using the most stringent conditions. (K) Luciferase expression
from Firefly-puΔtk-Gdnf 3’UTR construct in HEK293 cells after co-transfection with Gdnf-regu-
lating pre-miRs. Note that miRs that inhibit luciferase expression via the nativeGdnf 3’UTR (Fig
5B) do not suppress the expression from reporter construct containing the Firefly-puΔtk-Gdnf
3’UTR cassette. N = 3 experiments with 3–5 biological repeats. (L) Luciferase activity in an ATP-
based survival assay in U87 cells after co-transfection with pre-miRs. Note that the viability of
U87 cells is not affected by the overexpression of pre-miRs, compared to scrambled control pre-
miRs. N = 3 experiments with 3 replicates/experiment. (M) GdnfmRNA levels in HEK293 cells
after transfection with pAAV constructs encoding shRNAs against miR-9, miR-96 and miR-146.
A number of shRNA-coding plasmids from two different producers, Signagen (left panel) and
Vector Biosystems (right panel), were tested. N = 5 experiments with 2 repeats (all constructs
from Signagen) and N = 1–2 experiments (constructs from Vector Biosystems). $ indicates
that the constructs were tested 2 times with 2 repeats. The rest of the constructs from Vector
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Biosystems were tested once with 2 repeats. siRNA against Dicer was included as a positive con-
trol. N = 5 experiments with 2 repeats. Abbreviations: AAV, adeno-associated virus; RBP, RNA-
binding protein; GFP, green fluorescent protein; AUF1, AU-rich element binding protein 1;
ELAVL1, embryonic lethal, abnormal vision-like protein 1; TTP, tristetraprolin; puΔtk, a cassette
with PGK promoter encoding for fusion protein between puromycin N-acetyltransferase and a
truncated version of herpes simplex virus type 1 thymidine kinase (TK) with 3’ bovine growth
hormone polyadenylation signal; scr, scrambled control; pA, polyadenylation signal. P<0.05,
P<0.01, and P<0.001; error bars indicate SEM.
(TIF)
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